Abstract
Abstract Gene-transferred T -cell therapy such as chimeric antigen receptor (CAR) T-cell and cancer antigen specific T cell receptor (TCR) T -cell technology has seen a rapid development over the last decade mostly due to the potential that these cells may have in treating malignant diseases. While large multinational drug companies are currently investigating the potential role of CAR T-cells in hematological oncology, the potential of such cellular therapies are being recognized worldwide as they are expected to expand in the patient to support the establishment of the immune memory, provide a continuous surveillance to prevent and/or treat a relapse, and keep the targeted malignant cell subpopulation in check. In this lecture, the possible advantages of using gene transferred T cells in treating selected malignancies, including the new technology and the current knowledge in their preclinical and early clinical trial use, and management of the side effects such as cytokine release syndrome (CRS) will be presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
